Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Significance: Primary effusion lymphoma (PEL) is an AIDS-defining cancer. It is associated with Kaposi sarcoma-associated herpesvirus. To date, no sequencing studies have been conducted for this cancer. We used X chromosome-targeted next-generation sequencing to identify 33 genes with coding region mutations in 100% of cases, including in interleukin 1 receptor-associated kinase 1 (IRAK1). IRAK1 kinase modulates toll-like receptor signaling-mediated immune signaling. It binds to MyD88 adapter protein, which is mutated in a subset of diffuse large B-cell lymphomas. IRAK1, however, had not been linked to cancer. This IRAK1 mutant is constitutively active and essential for PEL survival. This highlights the importance of innate immunity signaling as drivers for cancer, particularly those caused by viruses. It also suggests IRAK1 kinase may be a potential target for therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation
Tarpey, P. S., Smith, R., Pleasance, E., Whibley, A., Edkins, S., Hardy, C., O'Meara, S., Latimer, C., Dicks, E., Menzies, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.367 · Cited by 603
Microdroplet-based PCR enrichment for large-scale targeted sequencing
Tewhey, R., Warner, J. B., Nakano, M., Libby, B., Medkova, M., David, P. H., Kotsopoulos, S. K., Samuels, M. L., Hutchison, J. B., Larson, J. W., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1583 · Cited by 454 · cited 1×
“We used RainDance technology for sequence enrichment (35) and TruSeq DNA Sample preparation Kit V2 (Illumina, catalog number FC-121–2001) for library preparation.”
MethodTargeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199 · cited 1×
“Finally, an IRAK1/4 inhibitor showed activity against Waldenström macroglobulinemia and myelodysplastic syndrome (33, 34).”
Background
Cited by
Kaymaz, Y., Oduor, C. I., Yu, H., Otieno, J. A., Ong'echa, J. M., Moormann, A. M., & Bailey, J. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0305 · Cited by 120
Biology and management of primary effusion lymphoma
Shimada, K., Hayakawa, F., & Kiyoi, H. (2018) · Blood · doi:10.1182/blood-2018-03-791426 · Cited by 103
Smout, M. J., Sotillo, J., Laha, T., Papatpremsiri, A., Rinaldi, G., Pimenta, R. N., Chan, L. Y., Johnson, M. S., Turnbull, L., Whitchurch, C. B., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005209 · Cited by 94
Hosseini, M. M., Kurtz, S. E., Abdelhamed, S., Mahmood, S., Davare, M. A., Kaempf, A., Elferich, J., McDermott, J. E., Liu, T., Payne, S. H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0112-2 · Cited by 65
Metadata
- Authors
- Yang, D., Chen, W., Xiong, J., Sherrod, C. J., Henry, D. H., & Dittmer, D. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-10-23
- Volume
- 111
- Issue
- 44
- Pages
- E4762-8
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2076651618
- Cited by
- 41
- References
- 3
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. https://app.cochat.ai/papers/10.1073/pnas.1405423111
- The paper
- Yang, D., Chen, W., Xiong, J., Sherrod, C. J., Henry, D. H., & Dittmer, D. P. (2014). Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1405423111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.